{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:31:23Z","timestamp":1790875883685,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07967-9","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:53:43Z","timestamp":1772880823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CD30 CAR-T cells in combination with anti-PD-1 camrelizumab in relapsed\/refractory CD30+ lymphomas"],"prefix":"10.1186","volume":"24","author":[{"given":"Min","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longzi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fancong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongcun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"7967_CR1","doi-asserted-by":"crossref","unstructured":"van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding cd30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017;7(9):e603.","DOI":"10.1038\/bcj.2017.85"},{"issue":"6","key":"7967_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/CCO.0b013e32834bb8a7","volume":"23","author":"A Younes","year":"2011","unstructured":"Younes A. Cd30-targeted antibody therapy. Curr. Opin. Oncol. 2011;23(6):587\u201393.","journal-title":"Curr. Opin. Oncol"},{"issue":"3","key":"7967_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/cancers17030496","volume":"17","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Dong S, Wang Y. Antibody-drug conjugates targeting cd30 in t-cell lymphomas: clinical progression and mechanism. Cancers (Basel). 2025;17(3):496.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"7967_CR4","first-page":"249","volume":"21","author":"A Mullard","year":"2022","unstructured":"Mullard A. Fda approves second bcma-targeted car-t cell therapy. Nat Rev Drug Discov. 2022;21(4):249.","journal-title":"Nat Rev Drug Discov"},{"key":"7967_CR5","doi-asserted-by":"crossref","unstructured":"Fda approves second car t-cell therapy. Cancer Discov. 2018;8(1):5\u20136.","DOI":"10.1158\/2159-8290.CD-NB2017-155"},{"issue":"9","key":"7967_CR6","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after cd30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Investigation. 2017;127(9):3462\u201371.","journal-title":"J Clin Investigation"},{"issue":"1","key":"7967_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41408-020-0274-9","volume":"10","author":"D Wang","year":"2020","unstructured":"Wang D, Zeng C, Xu B, Xu J, Wang J, Jiang L, et al. Anti-cd30 chimeric antigen receptor t cell therapy for relapsed\/refractory cd30(+) lymphoma patients. Blood Cancer J. 2020;10(1):8.","journal-title":"Blood Cancer J"},{"issue":"32","key":"7967_CR8","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu M, Ivanova A, et al. Anti-cd30 car-t cell therapy in relapsed and refractory hodgkin lymphoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2020;38(32):3794\u2013804.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"5","key":"7967_CR9","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"C Wang","year":"2017","unstructured":"Wang C, Wu Z, Wang Y, Guo Y, Dai H, Wang X, et al. Autologous t cells expressing cd30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: an open-label phase i trial. Clin Cancer Res: Off J Am Assoc Cancer Res. 2017;23(5):1156\u201366.","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"7967_CR10","doi-asserted-by":"crossref","unstructured":"Veyri M. The value of anti-cd30 car t cells in hodgkin lymphoma. The Lancet Haematol. 2024;11(5):e314\u20136.","DOI":"10.1016\/S2352-3026(24)00094-2"},{"issue":"6","key":"7967_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.hoc.2023.05.017","volume":"37","author":"IN Muhsen","year":"2023","unstructured":"Muhsen IN, Hill LC, Ramos CA. Chimeric antigen receptor t cells in hodgkin and t-cell lymphomas. Hematol\/Oncol Clinics N Am. 2023;37(6):1107\u201324.","journal-title":"Hematol\/Oncol Clinics N Am"},{"issue":"10","key":"7967_CR12","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","volume":"36","author":"MGM Roemer","year":"2018","unstructured":"Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, et al. Major histocompatibility complex class ii and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2018;36(10):942\u201350.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"6","key":"7967_CR13","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/ijc.33852","volume":"150","author":"J Wu","year":"2022","unstructured":"Wu J, Song Y, Chen X, Lin T, Cao J, Liu Y, et al. Camrelizumab for relapsed or refractory classical hodgkin lymphoma: extended follow-up of the multicenter, single-arm, phase 2 study. Int. J Cancer. 2022;150(6):984\u201392.","journal-title":"Int. J Cancer"},{"issue":"1","key":"7967_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-024-01825-0","volume":"9","author":"Y Gao","year":"2024","unstructured":"Gao Y, He H, Li X, Zhang L, Xu W, Feng R, et al. Sintilimab (anti-pd-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer t-cell lymphoma (scent): a phase ib\/ii study. Signal Transduct Target Ther. 2024;9(1):121.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"7967_CR15","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/iub.2558","volume":"73","author":"R Hosseinzadeh","year":"2021","unstructured":"Hosseinzadeh R, Feizisani F, Shomali N, Abdelbasset WK, Hemmatzadeh M, Gholizadeh Navashenaq J, et al. Pd-1\/pd-l1 blockade: prospectives for immunotherapy in cancer and autoimmunity. IUBMB Life. 2021;73(11):1293\u2013306.","journal-title":"IUBMB Life"},{"key":"7967_CR16","doi-asserted-by":"crossref","unstructured":"Ouyang W, Jin S, Xu N, Liu W, Zhao H, Zhang L, et al. Pd-1 downregulation enhances car-t cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion. J Immunother Cancer. 2024;12(4):e 8429.","DOI":"10.1136\/jitc-2023-008429"},{"issue":"8","key":"7967_CR17","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human car t cells with cell-intrinsic pd-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Investigation. 2016;126(8):3130\u201344.","journal-title":"J Clin Investigation"},{"issue":"11","key":"7967_CR18","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, et al. A phase i trial of regional mesothelin-targeted car t-cell therapy in patients with malignant pleural disease, in combination with the anti-pd-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748\u201363.","journal-title":"Cancer Discov"},{"issue":"12","key":"7967_CR19","first-page":"1178","volume":"30","author":"R Ram","year":"2024","unstructured":"Ram R, Amit O, Perry C, Herishanu Y, Avivi I, Sarid N, et al. Addition of nivolumab tailored by expansion of car-t cells in patients with stable\/progressive large b cell lymphoma at lymphodepletion-a phase 2, prospective interventional study. Transpl Cell Ther. 2024;30(12):1178\u201388.","journal-title":"Transpl Cell Ther"},{"issue":"11","key":"7967_CR20","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1182\/bloodadvances.2022007779","volume":"7","author":"U Jaeger","year":"2023","unstructured":"Jaeger U, Worel N, McGuirk JP, Riedell PA, Fleury I, Du Y, et al. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r\/r dlbcl: phase 1b portia study results. Blood Adv. 2023;7(11):2283\u201386.","journal-title":"Blood Adv"},{"issue":"1","key":"7967_CR21","doi-asserted-by":"publisher","first-page":"10488","DOI":"10.1038\/s41598-022-14523-0","volume":"12","author":"S Zhang","year":"2022","unstructured":"Zhang S, Gu C, Huang L, Wu H, Shi J, Zhang Z, et al. The third-generation anti-cd30 car t-cells specifically homing to the tumor and mediating powerful antitumor activity. Sci Rep. 2022;12(1):10488.","journal-title":"Sci Rep"},{"issue":"27","key":"7967_CR22","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. J Clin Oncol: Off J Am Soc Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"1","key":"7967_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12885-024-13400-5","volume":"25","author":"F Meng","year":"2025","unstructured":"Meng F, Xiang M, Liu Y, Zeng D. Safety and efficacy of anti-cd30 car-t cell therapy in relapsed\/refractory classic hodgkin lymphoma: a systematic review and meta-analysis. BMC Cancer. 2025;25(1):78.","journal-title":"BMC Cancer"},{"issue":"14","key":"7967_CR24","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1080\/10428194.2021.1957865","volume":"62","author":"WJ Plattel","year":"2021","unstructured":"Plattel WJ, Bergamasco A, Trinchese F, Gavini F, Bent-Ennakhil N, Zomas A, et al. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory hodgkin lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2021;62(14):3320\u201332.","journal-title":"Leuk Lymphoma"},{"key":"7967_CR25","doi-asserted-by":"publisher","first-page":"1389971","DOI":"10.3389\/fimmu.2024.1389971","volume":"15","author":"BP Satapathy","year":"2024","unstructured":"Satapathy BP, Sheoran P, Yadav R, Chettri D, Sonowal D, Dash CP, et al. The synergistic immunotherapeutic impact of engineered car-t cells with pd-1 blockade in lymphomas and solid tumors: a systematic review. Front Immunol. 2024;15:1389971.","journal-title":"Front Immunol"},{"key":"7967_CR26","doi-asserted-by":"publisher","first-page":"858021","DOI":"10.3389\/fimmu.2022.858021","volume":"13","author":"W Sang","year":"2022","unstructured":"Sang W, Wang X, Geng H, Li T, Li D, Zhang B, et al. Anti-pd-1 therapy enhances the efficacy of cd30-directed chimeric antigen receptor t cell therapy in patients with relapsed\/refractory cd30+ lymphoma. Front Immunol. 2022;13:858021.","journal-title":"Front Immunol"},{"issue":"1","key":"7967_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-025-01257-1","volume":"15","author":"TJ Voorhees","year":"2025","unstructured":"Voorhees TJ, McLaughlin EM, Torka P, Florindez J, Kim NH, Moyo TK, et al. Outcomes in patients with classic hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-pd-1 therapy: a real world analysis from 15 u.s. Academic centers. Blood Cancer J. 2025;15(1):45.","journal-title":"Blood Cancer J"},{"issue":"6","key":"7967_CR28","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1182\/blood.2021013881","volume":"139","author":"DH Kim","year":"2022","unstructured":"Kim DH, Vega F. Relapsed classic hodgkin lymphoma with decreased cd30 expression after brentuximab and anti-cd30 car-t therapies. Blood. 2022;139(6):951.","journal-title":"Blood"},{"issue":"5","key":"7967_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/17474086.2025.2492936","volume":"18","author":"H Zhang","year":"2025","unstructured":"Zhang H, Yan Y, Yi S, Sun Q. Advancements in targeting cd30 for lymphoma therapy: a historical perspective and future directions. Expert Rev Hematol. 2025;18(5):373\u201386.","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"7967_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/17474086.2021.1955344","volume":"14","author":"K Karube","year":"2021","unstructured":"Karube K, Kakimoto Y, Tonozuka Y, Ohshima K. The expression of cd30 and its clinico-pathologic significance in peripheral t-cell lymphomas. Expert Rev Hematol. 2021;14(8):777\u201387.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"7967_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00277-022-05054-9","volume":"102","author":"HM Prince","year":"2023","unstructured":"Prince HM, Hutchings M, Domingo-Domenech E, Eichenauer DA, Advani R. Anti-cd30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives. Ann Hematol. 2023;102(1):13\u201329.","journal-title":"Ann Hematol"},{"issue":"3","key":"7967_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","volume":"20","author":"SM Horwitz","year":"2022","unstructured":"Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, et al. T-cell lymphomas, version 2. 2022, nccn clinical practice guidelines in oncology. J Natl Compr Cancer Network: JNCCN. 2022;20(3):285\u2013308.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"2","key":"7967_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41417-021-00295-8","volume":"29","author":"Y Wu","year":"2022","unstructured":"Wu Y, Chen D, Lu Y, Dong S, Ma R, Tang W, et al. A new immunotherapy strategy targeted cd30 in peripheral t-cell lymphomas: car-modified t-cell therapy based on cd30 mab. Cancer Gene Ther. 2022;29(2):167\u201377.","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"7967_CR34","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","volume":"8","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Natrakul DA, Karrs J, Patel N, Maass-Moreno R, Ahlman MA, et al. Transient responses and significant toxicities of anti-cd30 car t cells for cd30+ lymphomas: results of a phase 1 trial. Blood Adv. 2024;8(3):802\u201314.","journal-title":"Blood Adv"},{"issue":"23","key":"7967_CR35","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.1182\/bloodadvances.2020003218","volume":"4","author":"TJ Voorhees","year":"2020","unstructured":"Voorhees TJ, Ghosh N, Grover N, Block J, Cheng C, Morrison K, et al. Long-term remission in multiply relapsed enteropathy-associated t-cell lymphoma following cd30 car t-cell therapy. Blood Adv. 2020;4(23):5925\u201328.","journal-title":"Blood Adv"},{"key":"7967_CR36","doi-asserted-by":"crossref","unstructured":"Grover NS, Hucks G, Riches ML, Ivanova A, Moore DT, Shea TC, et al. Anti-cd30 car t cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk cd30(+) lymphoma: a phase 1 study. The Lancet Haematol. 2024;11(5):e358\u201367.","DOI":"10.1016\/S2352-3026(24)00064-4"},{"issue":"1","key":"7967_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/cancers16010046","volume":"16","author":"C Benevolo Savelli","year":"2023","unstructured":"Benevolo Savelli C, Clerico M, Botto B, Secreto C, Cavallo F, Dellacasa C, et al. Chimeric antigen receptor-t cell therapy for lymphoma: new settings and future directions. Cancers (Basel). 2023;16(1):46.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"7967_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/bloodadvances.2023011287","volume":"8","author":"AV Hirayama","year":"2024","unstructured":"Hirayama AV, Kimble EL, Wright JH, Fiorenza S, Gauthier J, Voutsinas JM, et al. Timing of anti-pd-l1 antibody initiation affects efficacy\/toxicity of cd19 car t-cell therapy for large b-cell lymphoma. Blood Adv. 2024;8(2):453\u201367.","journal-title":"Blood Adv"},{"key":"7967_CR39","doi-asserted-by":"publisher","first-page":"1093194","DOI":"10.3389\/fphar.2023.1093194","volume":"14","author":"Q Tang","year":"2023","unstructured":"Tang Q, Wu D, Huang H, Fang H, Wu Y, Liu F, et al. Adverse events of pd-(l)1 inhibitors plus anti-vegf(r) agents compared with pd-(l)1 inhibitors alone for cancer patients: a systematic review and meta-analysis. Front Pharmacol. 2023;14:1093194.","journal-title":"Front Pharmacol"},{"issue":"1","key":"7967_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","volume":"34","author":"JS Abramson","year":"2020","unstructured":"Abramson JS. Anti-cd19 car t-cell therapy for b-cell non-hodgkin lymphoma. Transfus Med Rev. 2020;34(1):29\u201333.","journal-title":"Transfus Med Rev"},{"issue":"18","key":"7967_CR41","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-bcma car t-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726\u201337.","journal-title":"NEJM Evid"},{"issue":"4","key":"7967_CR42","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/bloodadvances.2021005385","volume":"6","author":"TJ Voorhees","year":"2022","unstructured":"Voorhees TJ, Zhao B, Oldan J, Hucks G, Khandani A, Dittus C, et al. Pretherapy metabolic tumor volume is associated with response to cd30 car t cells in hodgkin lymphoma. Blood Adv. 2022;6(4):1255\u201363.","journal-title":"Blood Adv"},{"issue":"3","key":"7967_CR43","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/bjh.15801","volume":"185","author":"A Romano","year":"2019","unstructured":"Romano A, Parrinello NL, Chiarenza A, Motta G, Tibullo D, Giallongo C, et al. Immune off-target effects of brentuximab vedotin in relapsed\/refractory hodgkin lymphoma. Br J Haematol. 2019;185(3):468\u201379.","journal-title":"Br J Haematol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07967-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07967-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07967-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:07:31Z","timestamp":1776247651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07967-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7967"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07967-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committees of the First Affiliated Hospital of Nanchang University and Tongji Medical College, Huazhong University of Science and Technology. All patients provided written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has been presented in part at the ASH (2024) annual meeting.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}}],"article-number":"507"}}